Odds stacked against Ebola’s newest drugs
The effectiveness of Ebola’s latest preferred drugs hinges on a number of factors that are beyond the control of the...
Paul Adepoju is an academic, journalist, author, geneticist, local content creator and media entrepreneur. He teaches genetics and histopathology at Nigeria's Babcock University and he covers health and tech in Africa for CNN, Quartz and several others. He's also the founder and managing editor of HealthNews.NG and healthnews.africa. He is completing a doctorate in cell biology and genetics at Nigeria's premier university, the University of Ibadan.
The effectiveness of Ebola’s latest preferred drugs hinges on a number of factors that are beyond the control of the...
According to the 2018 WHO country profile, non-communicable diseases (NCDs) accounted for an estimated 29% of all deaths in Nigeria...
For at least five weeks, the website of Nigeria's National Health Insurance Scheme (NHIS) has been down, healthnews.ng can exclusively...
This week, healthnews.ng reported the spread of the Ebola virus disease to Uganda. The index patient, a 5-year-old child from...
On World Tobacco Day, the World Health Organisation (WHO) is drawing attention to the damage caused by tobacco to lung...
The World Bank has revealed that about 3.4 billion people across the world who earn US$5.50 a day or less...
To address vaccination challenges in the ongoing Ebola outbreak in the Democratic Republic of the Congo (DRC), WHO’s Strategic Advisory...
In 2019, more than 141 million children will be born: 73 million boys and 68 million girls. Based on recent...
Health worker in DR Congo receiving the experimental Ebola vaccine More than 90% of people eligible for vaccination against the...
A new research concluded that treatment of HIV-positive children with efavirenz, a popular HIV drug, is associated with a mild...
© 2017 HealthNews.NG - Owned by Glumedia Company.